RGNX Positive Sentiment
REGENXBIO to Participate in Upcoming Investor Conference
Tuesday, November 25, 2025 BiopharmaWatch Research 1 min read Key Takeaway: REGENXBIO Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The event will feature a fireside chat at 8:30 a.m. ET in New York, NY. Investors can access a live webcast on the company's website, with an archived replay available for 30 days post-event. REGENXBIO focuses on gene therapy for rare and retinal diseases.
Full Press Release Details
ROCKVILLE, Md.,Nov. 25, 2025/PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX) today announced it will participate in the following investor conference:
Piper Sandler 37thAnnual Healthcare ConferenceFireside Chat:Tuesday, December 2 at 8:30 a.m. ETLocation:New York, NY
A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at
www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the event.
ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visitWWW.REGENXBIO.COM.